Compare iShares MSCI South Africa ETF (EZA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Summit Therapeutics Inc — how do they compare? iShares MSCI South Africa ETF trades at $68.53, while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: iShares MSCI South Africa ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EZA | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $26.98 |
52-Week Low | $56.57 | $12.55 |
Market Cap | — | $12.06B |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $68.33, down 2.01% today, with a bullish technical bias from moving averages but bearish oscillators. Key support is at $68 and resistance at $70. The company has a dividend scheduled for June 2026, but financial ratios like P/E and P/S are not provided in the data.
Outlook is mixed: technical strength contrasts with macroeconomic headwinds highlighted in recent news. Risks include exposure to South African sectors sensitive to interest rates and commodities. Investment appeal hinges on navigating these challenges amid a bullish trend signal.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
